Cure My Disease

Don't miss your cure!

 Log in / Sign up

Epigenetic clues could link bone loss and brain decline

NCT ID NCT03401619

Knowledge-focused Sponsor: Peking University Third Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 02, 2026 · Last updated Oct 02, 2026

Summary

Researchers at Peking University Third Hospital are following 2,000 people who have osteoporosis along with neurological disorders such as cognitive impairment. The study combines a look back at medical records from 2007 to 2017 with a forward follow-up from 2017 to 2027. They will measure bone density, bone metabolism markers, imaging, fracture rates, and cognitive function to see how epigenetic modifications relate to these outcomes. The goal is to understand whether epigenetic changes influence the course of osteoporosis and neurological disorders, which could inform future research into causes and treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A combination of exercise, nutrition, bisphosphonates, statins, calcitonin, and vitamin D
What this could lead to
If the study finds links between epigenetic changes and bone or brain health, it could guide future research into treatments for osteoporosis and neurological disorders.
What could go wrong
This is an observational cohort study, so it can show associations but cannot prove cause and effect. Results may not apply to other populations, and the long follow-up means many factors could influence the findings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2017

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Volunteer, outpatient, inpatient

Ages

45 to 105 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Normal hearing, vision, and pronunciation * DEXA examination Exclusion Criteria: * Mental retardation * Blindness, deafness, and dumb * Severe schizophrenia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Osteoporosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

osteoporosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Osteoporosis，neurological disorders

Contacts and locations

Locations

  • Peking University Third Hospital

    Beijing, Beijing Municipality, 100191, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.